Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-05-22
2007-05-22
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S050000, C536S028100, C534S011000, C424S001850, C424S001730
Reexamination Certificate
active
10671376
ABSTRACT:
Radiolabeled conjugates are disclosed which have a component that is effective to target tumor cells, which cells selectively take up and degrade the conjugate, thereby delivering to the tumor cell nucleus a radioisotope capable of being incorporated into the nuclear material, so as to produce a cytotoxic effect and/or to render the cell detectable by radioimaging.
REFERENCES:
patent: 5096694 (1992-03-01), Quivy et al.
patent: 5468853 (1995-11-01), Baranowska-Kortylewicz
patent: 1059990 (1998-03-01), None
patent: WO 90/03799 (1990-04-01), None
Downer, J.B. et al, Nuclear Medicine and Biology, 2001, 28, 613-626.
Bonasera, T.A. et al. “Preclinical Evaluation of Fluorine-18-Labeled Androgen Receptor Ligands in Baboons”; Journal of Nuclear Medicine, 37(6): 1009-1015 (1996).
Choe, Y.S. et al. “Synthesis of 11β-[18F]Fluro-5α-dihydrotestosterone and 11β-[18F]Fluoro-19-nor-5α-dihydrotestosterone: Preparation via Halofluorination-Reduction, Receptor Binding, and Tissue Distribution”; Journal of Medicinal Chemistry, 38(5): 816-825 (1995).
Downer, J.B. et al. “Comparison of animal models for the evaluation of radiolabeled androgens”; Nuclear Medicine and Biology, 28(6): 613-626 (2001).
Hoyte, R.M. et al. “7α-Methyl-17α-(E-2′-[125I]iodovinyl)-19-nortestostererone: a new radioligand for the detection of androgen receptor”; Steroids, 58(1): 13-23 (1993).
Labaree, D.C. et al. “7α-Iodine-125-Iodo-5α-Dihydrotestosterone: A Radiolabeled Ligand for the Androgen Receptor”; Journal of Nuclear Medicine, 38(3): 402-409 (1997).
Lara, P.N. et al. “Treatment Options in Androgen-Independent Prostate Cancer”; Cancer Investigation, 17(2): 137-144 (1999).
Liu, A. et al. “Fluorine-18-Labeled Androgens: Radiochemical Synthesis and Tissue Distribution Studies on Six Fluorine-Substituted Androgens, Potential Imaging Agents for Prostatic Cancer”; Journal of Nuclear Medicine, 33(5): 724-734 (1992).
Salman, M. et al. “A Potential Radioiodinated Ligand for Androgen Receptor: 7α-Methyl-17α-(2′-(E)-iodovinyl)-19-nortestosterone”; Journal of Medicinal Chemistry, 34(3): 1019-1024 (1991).
Van Den Bos, J.C., et al. “New Iodinated Progestins as Potential Ligands for Progesterone Receptor Imaging in Breast Cancer. Part 1: Synthesis andin VitroPharmacological Characterization”; Nuclear Medicine & Biology, 25(8): 781-789 (1998).
Warters, R.L. et al. “Radionuclide Toxicity in Cultured Mammalian Cells: Elucidation of the Primary Site of Radiation Damage”; Current Topics in Radiation Research Quarterly, 12: 389-407 (1997).
Makrigiorgos, G.M. et al. “Radiotoxicity of 5-[123I]iodo-2′-deoxyuridine in V79 Cells: A Comparison with 5-[125I]Iodo-2′-deoxyuridine”; Radiation Research, 118: 532 (1989).
Baranowska-Kortylewicz, J. et al. “5-[123I]Iodo-2′-Deoxyuridine in the Radiotherapy of an Early Ascites Tumor Model”; Int. J. Radiat. Oncol. Biol. Phys., 21: 1541-1551 (1991).
Kyriakos, R.J. et al. “The Fate of Antibodies Bound to the Surface of Tumor Cellsin Vitro”; Cancer Research, 52: 835-842 (1992).
Bryan, R.M. et al. “Androgen Receptors in Breast Cancer”; Cancer, 54: 2436-2440 (1984).
Lea, O.A. et al. “Improved Measurement of Androgen Receptors in Human Breast Cancer”; Cancer Research, 49: 7162-7167 (1989).
Soreide, J.A. et al. “Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment”; European Journal of Surgical Oncology, 18: 112-118 (1992).
Poulin, R. et al. “Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line”; Breast Cancer Research and Treatment, 12: 213-225 (1988).
Ingle, J.N. et al. “Combination Hormonal Therapy With Tamoxifen Plus Fluoxymesterone Versus Tamoxifen Alone in Postmenopausal Women With Metastatic Breast Cancer”; Cancer, 67: 886-891 (1991).
Mariani, G. et al. “Tumor Targeting Potential and Metabolism of 5-[125I]Iodo-2′-Deoxyuridine Injected Intratumorally in Patients with Breast Cancer”; Ann N Y Acad. Sci., 698: 204-211 (1993).
Baranowska-Kortylewicz Janina
Kortylewicz Zbigniew
Board of Regents of the University of Nebraska
Dann Dorfman Herrell and Skillman, P.C.
Hagan Patrick J.
Jiang Shaojia Anna
Krishnan Ganapathy
LandOfFree
Cancer specific radiolabeled conjugates regulated by the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer specific radiolabeled conjugates regulated by the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer specific radiolabeled conjugates regulated by the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3755528